CoChat
Sign Up
Cited by 188

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis

Koschmieder, Steffen, Göttgens, Berthold, Zhang, Pu, Iwasaki-Arai, Junko, Akashi, Koichi, Kutok, Jeffery L., Dayaram, Tajhal, Geary, Kristin, Green, Anthony R., Tenen, Daniel G., Huettner, Claudia S.·2005·Blood
DOI 10.1182/blood-2003-12-4369
Open this paper in CoChat — free account

Abstract

To develop murine models of leukemogenesis, a series of transgenic mice expressing BCR-ABL in different hematopoietic cell subsets was generated. Here we describe targeted expression of P210 BCR-ABL in stem and progenitor cells of murine bone marrow using the tet-off system. The transactivator protein tTA was placed under the control of the murine stem cell leukemia (SCL) gene 3′ enhancer. Induction of BCR-ABL resulted in neutrophilia and leukocytosis, and the mice became moribund within 29 to 122 days. Autopsy of sick mice demonstrated splenomegaly, myeloid bone marrow hyperplasia, and extramedullary myeloid cell infiltration of multiple organs. BCR-ABL mRNA and protein were detectable in the affected organs. Fluorescence-activated cell sorter (FACS) analysis demonstrated a significant increase in mature and immature myeloid cells in bone marrow and spleen, together with increased bilineal B220+/Mac-1+ cells in the bone marrow. tTA mRNA was expressed in FACS-sorted hematopoietic stem cells expanded 26-fold after BCR-ABL induction. Thirty-one percent of the animals demonstrated a biphasic phenotype, consisting of neutrophilia and subsequent B-cell lymphoblastic disease, reminiscent of blast crisis. In summary, this mouse model recapitulates many characteristics of human chronic myeloid leukemia (CML) and may help elucidate basic leukemogenic mechanisms in CML stem cells during disease initiation and progression. (Blood. 2005;105:324-334)

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2003-12-4369

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 6 references

Research works printed but not linked: 50

  1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science.1960;132: 1197-1200.
  2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science.1990;247: 824-830. · DOI · Paper page
  3. Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia in bcr/abl transgenic mice. Nature.1990;344: 251-253. · DOI
  4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med.2002;346: 645-652. · DOI
  5. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci U S A.1967;58: 1468-1471. · DOI
  6. Honda H, Fujii T, Takatoku M, et al. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood.1995;85: 2853-2861. · DOI
  7. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet.2000;24: 57-60. · DOI
  8. Huettner CS, Koschmieder S, Iwasaki H, et al. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood.2003;102: 3363-3370. · DOI
  9. Miles C, Sanchez MJ, Sinclair A, Dzierzak E. Expression of the Ly-6E.1 (Sca-1) transgene in adult hematopoietic stem cells and the developing mouse embryo. Development.1997;124: 537-547. · DOI
  10. Domen J, Cheshier SH, Weissman IL. The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med.2000;191: 253-264. · DOI
  11. Codias EK, Cray C, Baler RD, Levy RB, Malek TR. Expression of Ly-6A/E alloantigens in thymocyte and T-lymphocyte subsets: variability related to the Ly-6a and Ly-6b haplotypes. Immunogenetics.1989;29: 98-107. · DOI
  12. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science.1988;241: 58-62. · DOI
  13. Morello D, Moore G, Salmon AM, Yaniv M, Babinet C. Studies on the expression of an H-2K/human growth hormone fusion gene in giant transgenic mice. EMBO J.1986;5: 1877-1883. · DOI
  14. Okuno Y, Iwasaki H, Huettner CS, et al. Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc Natl Acad Sci U S A.2002;99: 6246-6251. · DOI
  15. Radomska HS, Gonzalez DA, Okuno Y, et al. Transgenic targeting with regulatory elements of the human CD34 gene. Blood.2002;100: 4410-4419. · DOI
  16. Drake CJ, Brandt SL, Trusk TC, Little CD. TAL1/SCL is expressed in endothelial progenitor cells/angioblasts and defines a dorsal-to-ventral gradient of vasculogenesis. Dev Biol.1997;192: 17-30. · DOI
  17. Green AR, Lints T, Visvader J, Harvey R, Begley CG. SCL is coexpressed with GATA-1 in hemopoietic cells but is also expressed in developing brain. Oncogene.1992;7: 653-660.
  18. Kallianpur AR, Jordan JE, Brandt SJ. The SCL/TAL-1 gene is expressed in progenitors of both the hematopoietic and vascular systems during embryogenesis. Blood.1994;83: 1200-1208. · DOI
  19. Begley CG, Aplan PD, Denning SM, et al. The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A.1989;86: 10128-10132. · DOI
  20. Green AR, Salvaris E, Begley CG. Erythroid expression of the helix-loop-helix gene, SCL. Oncogene.1991;6: 475-479.
  21. Mouthon MA, Bernard O, Mitjavila MT, et al. Expression of tal-1 and GATA-binding proteins during human hematopoiesis. Blood.1993;81: 647-655. · DOI
  22. Visvader J, Begley CG, Adams JM. Differential expression of the LYL, SCL and E2A helix-loop-helix genes within the hemopoietic system. Oncogene.1991;6: 187-194.
  23. Porcher C, Swat W, Rockwell K, et al. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell.1996;86: 47-57. · DOI
  24. Robb L, Lyons I, Li R, et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci U S A.1995;92: 7075-7079. · DOI · Paper page
  25. Robb L, Elwood NJ, Elefanty AG, et al. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J.1996;15: 4123-4129. · DOI
  26. Elefanty AG, Begley CG, Metcalf D, et al. Characterization of hematopoietic progenitor cells that express the transcription factor SCL, using a lacZ “knock-in” strategy. Proc Natl Acad Sci U S A.1998;95: 11897-11902. · DOI
  27. Sanchez M, Gottgens B, Sinclair AM, et al. An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors. Development.1999;126: 3891-3904. · DOI
  28. Sanchez MJ, Bockamp EO, Miller J, Gambardella L, Green AR. Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing Scl under the control of a stem cell enhancer. Development.2001;128: 4815-4827. · DOI
  29. Göttgens B, Nastos A, Kinston S, et al. Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO J.2002;21: 3039-3050. · DOI · Paper page
  30. Iwama A, Zhang P, Darlington GJ, et al. Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPalpha. Nucleic Acids Res.1998;26: 3034-3043. · DOI · Paper page
  31. Okuno Y, Huettner CS, Radomska HS, et al. Distal elements are critical for human CD34 expression in vivo. Blood.2002;100: 4420-4426. · DOI
  32. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A.1993;90: 3755-3759. · DOI
  33. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood.1998;92: 3780-3792. · DOI
  34. Sexl V, Piekorz R, Moriggl R, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood.2000;96: 2277-2283. · DOI
  35. Schweiger M, Lohler J, Friel J, et al. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med.2002;196: 1227-1240. · DOI
  36. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood.1988;71: 831-843. · DOI
  37. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med.1991;173: 1213-1225. · DOI
  38. Karlsson A, Deb-Basu D, Cherry A, et al. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A.2003;100: 9974-9979. · DOI
  39. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet.2002;30: 48-58. · DOI
  40. Million RP, Aster J, Gilliland DG, Van Etten RA. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood.2002;99: 4568-4577. · DOI
  41. Dazzi F, Hasserjian R, Gordon MY, et al. Normal and chronic phase CML hematopoietic cells re-populate NOD/SCID bone marrow with different kinetics and cell lineage representation. Hematol J.2000;1: 307-315. · DOI
  42. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell.2001;104: 21-32. · DOI
  43. Kelly LM, Liu Q, Kutok JL, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood.2002;99: 310-318. · DOI
  44. Jaiswal S, Traver D, Miyamoto T, et al. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci U S A.2003;100: 10002-10007. · DOI
  45. Westervelt P, Lane AA, Pollock JL, et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood.2003;102: 1857-1865. · DOI
  46. Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood.1993;81: 2386-2393. · DOI
  47. So CW, Karsunky H, Passegue E, et al. MLLGAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell.2003;3: 161-171. · DOI
  48. Holmes KL, Pierce JH, Davidson WF, Morse HC III. Murine hematopoietic cells with pre-B or pre-B/myeloid characteristics are generated by in vitro transformation with retroviruses containing fes, ras, abl, and src oncogenes. J Exp Med.1986;164: 443-457. · DOI
  49. Dannaeus K, Johannisson A, Nilsson K, Jonsson JI. Flt3 ligand induces the outgrowth of Mac-1+B220+ mouse bone marrow progenitor cells restricted to macrophage differentiation that coexpress early B cell-associated genes. Exp Hematol.1999;27: 1646-1654. · DOI
  50. Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med.2003;349: 1451-1464. · DOI

Cited by

Metadata

Authors
Koschmieder, S., Göttgens, B., Zhang, P., Iwasaki-Arai, J., Akashi, K., Kutok, J. L., Dayaram, T., Geary, K., Green, A. R., Tenen, D. G., & Huettner, C. S.
Affiliations
From the Department of Hematology/Oncology, Harvard Institutes of Medicine, Harvard Medical School, Boston, MA; Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, United Kingdom; Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Pathology, Brigham and Women's Hospital, Boston, MA; and Blood Center of South Eastern Wisconsin, Milwaukee.
Venue
Blood
Publisher
American Society of Hematology
Published
2005-01-01
Volume
105
Issue
1
Pages
324-334
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2003-12-4369
Cited by
188
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review